Why MedTech Founders Shouldn’t Delegate FDA Compliance
As a founder, you already know compliance matters. What you may not know is how fast it stops being your engineer’s problem and starts being yours.
Medical Devices Are 80% Paperwork
Getting a medical device approved is only 20% about the technology and 80% about the paperwork. In other words, the hardware and software you’re building are only part of what the FDA evaluates. The more important piece is documented evidence that you designed it safely, tested it rigorously, and can manufacture it consistently.
That documentation is your product’s legal right to exist in the U.S. market.
Founders who treat it as an engineering chore tend to miss this. They assume the quality management system (QMS) is something the regulatory lead handles quietly in the background. Then inspection day comes, and you’re answering questions about design history files and complaint-handling procedures.
More importantly, the FDA is paying more and more attention these days. In FY2022, they issued 538 Form 483 observations to medical device firms, nearly three times what they had done the prior year. Inspections have continued to rise since, and the escalation rate has increased with them.
How Compliance Debt Ends Companies
Enforcement follows a well-documented path, and it moves faster than most founders expect.
It starts with a Form 483 at the close of an inspection. That’s the FDA saying, “Show us your system works.” Respond well and the matter often ends there. Respond poorly and you’re in trouble: research shows more than 50% of inadequately handled 483s escalate to a warning letter.
Warning letters are public, widely reported, and increasingly common in MedTech. In FY2024, the FDA issued 47 warning letters to medical device firms, a 96% increase over the prior year. Once you’re on that list, your customers know, and your next investor knows before your first meeting.
The costs compound from there. The industry as a whole absorbs between $7.5 billion and $9 billion per year in non-compliance costs, plus another $1-2 billion in lost sales. A single major recall can run up to $600 million before litigation. Warning letters and recalls tend to travel together: a weak process that produces one usually produces the other.
For a startup or growth-stage company, any of these can be terminal. For a founder, they’re the fastest way to lose a board’s confidence.
The bottom line is if your business unit does $400 million in annual revenue, plan on setting aside at least $60 million to resolve a single FDA warning letter.
That figure comes from the industry benchmark known as the 15% rule, and it only covers direct remediation. Translation: you’ll also have to think about lost sales, the recall that often follows, the investor conversations to regain trust, and the 18 months your team spends cleaning up instead of shipping the next product…
How Business Pressure Erodes Your QMS
Compliance rarely fails all at once. It fails slowly, under the weight of ordinary business pressure.
We’ve watched it happen dozens of times. A launch date slips, so someone signs off on a design review that should have taken another week. Then maybe a supplier swaps a component. No big deal right? Or perhaps the change control process gets shortened so you can hit a shipping commitment. These kinds of decisions feel small in the moment. But when they pile up over 18 months, they become the reason the FDA shows up with a clipboard.
The FY2024 data bears this out. Design controls (21 CFR 820.30) were cited in 21 warning letters, the most of any category. CAPA failures appear in more than 60% of all enforcement actions. These are process discipline problems, and process discipline is a leadership responsibility.
If your QMS can’t hold up under commercial pressure, commercial pressure will eventually win. The enforcement data is clear on that.
Right-Size Regulatory. Always.
Most consultants in our space push regulatory-first thinking. We take a different view. We believe in right-sized regulatory, applied consistently at every stage of the product lifecycle.
Right-sized means compliance is built into your design process from the start, proportional to your device’s risk classification, scaled to the stage you’re in. It isn’t over-engineering a Class II device as if it were a Class III. It isn’t paralyzing an early-stage team with documentation they don’t yet need. And it isn’t deferring QMS work until you’re preparing for submission.
We’ve worked with founders on both ends of this mistake. Some stall for a year by over-specifying processes that aren’t required yet. Others move fast for two years and then discover that their design history file can’t survive an audit. But you can scale easier and faster when your leadership treats QMS like a system that’s worth owning.
The Takeaway
Compliance protects your reputation, but also your company’s ability to exist three years from now.
The companies that scale are the ones who own their compliance strategy the same way they own their product roadmap. They aren’t writing the SOPs themselves, but they understand how the system works, knowing both where it’s strongest and where it’s under pressure.
If you’d like to pressure-test your QMS before the FDA does, we’d welcome the conversation. Schedule a call with Justin and the Concise Engineering team, and let’s make sure your compliance foundation is built for where you’re going.
Justin Bushko
President, Concise Engineering
Next Steps
We hope you find this newsletter valuable and insightful.
If you have any questions, if you have feedback or would like to explore any specific topics further, please feel free to reach out to us.
Please email me at jbushko@concise-engineering.com or to book a call with me, click this link.
Stay tuned for future editions where we'll continue to share valuable information and industry updates.